Prediction of metabolism by cytochrome P450 2C9: Alignment and docking studies of a validated database of substrates

Journal of Medicinal Chemistry

Volumn 51, Issue 4, 2008, Pages 780-791

  Sykes, Matthew J ^a   McKinnon, Ross A ^b   Miners, John O ^a  

^a FLINDERS MEDICAL CENTRE   (Australia)

^b UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C9; HEME; IRON; LIGAND;

ARTICLE; CHEMICAL ANALYSIS; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME METABOLISM; ENZYME SUBSTRATE; PREDICTIVE VALIDITY;

ARYL HYDROCARBON HYDROXYLASES; BINDING SITES; DATABASES, FACTUAL; FLURBIPROFEN; HUMANS; LIGANDS; MODELS, MOLECULAR; PHARMACEUTICAL PREPARATIONS; PROTEIN BINDING;

EID: 39749093726     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm7009793     Document Type: Article

References (87)

1. Denisov, I. G.; Makris, T. M.; Sugar, S. G.; Schlichting, I. Structure and Chemistry of Cytochrome P450. Chem. Rev. 2005, 105, 2253-2277.
2. Paine, M. F.; Hart, H. L.; Ludington, S. S.; Haining, R. L.; Rettie, A. E.; Zeldin, D. C. The Human Intestinal Cytochrome P450 "PIE". Drug Metab. Dispos. 2006, 34, 880-886.
3. Shimada, T.; Yamazaki, H.; Mimura, M.; Inui, Y.; Guengerich, F. P. Interindividual Variations in Human Liver Cytochrome P-450 Enzymes Involved in the Oxidation of Drugs, Carcinogens and Toxic Chemicals: Studies with Liver Microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther. 1994, 270, 414-423.
4. Miners, J. O.; Birkett, D. J. Cytochrome P4502C9: An Enzyme of Major Importance in Human Drug Metabolism. Br. J. Clin. Pharmacol. 1998, 45, 525-538.
5. Hamman, M. A.; Thompson, G. A.; Hall, S. D. Regioselective and Stereoselective Metabolism of Ibuprofen by Human Cytochrome P450 2C. Biochem. Pharmacol. 1997, 54, 33-41.
6. Miners, J. O.; Coulter, S.; Tukey, R. H.; Veronese, M. E.; Birkett, D. J. Cytochromes P450. 1A2, and 2C9 are Responsible for the Human Hepatic O-Demethylation of R- and S-Naproxen. Biochem. Pharmacol. 1996, 51, 1003-1008.
7. Yamazaki, H.; Inoue, K.; Chiba, K.; Ozawa, N.; Kawai, T.; Suzuki, Y.; Goldstein, J. A.; Guengerich, F. P.; Shimada, T. Comparative Studies on the Catalytic Roles of Cytochrome P450 2C9 and its Cys-and Leu- Variants in the Oxidation of Warfarin, Flurbiprofen, and Diclofenac by Human Liver Microsomes. Biochem. Pharmacol. 1998, 56, 243-251.
8. Komatsu, K.; Ito, K.; Nakajima, Y.; Kanamitsu, S. I.; Imaoka, S.; Funae, Y.; Green, C. E.; Tyson, C. A.; Shimada, N.; Sugiyama, Y. Prediction of In Vivo Drug-Drug Interactions Between Tolbutamide and Various Sulfonamides in Humans Based on In Vitro Experiments. Drug Metab. Dispos. 2000, 28, 475-481.
9. Giancarlo, G. M.; Venkatakrislinan, K.; Granda, B. W.; Von Moltke, L. L.; Greenblatt, D. J. Relative Contributions of CYP2C9 and 2C19 to Phenytoin 4-Hydroxylation In Vitro: Inhibition by Sulfaphenazole, Omeprazole, and Ticlopidine. Eur. J. Clin. Pharmacol. 2001, 57, 31-36.
10. Miners, J. O.; Rees, D. L. P.; Valente, L.; Veronese, M. E.; Birkett, D. J. Human Hepatic P450 2C9 Catalyses the Rate-Limiting Pathway of Torsemide Metabolism. J. Pharmacol. Exp. Ther. 1995, 272, 1076-1081.
11. Usmani, K. A.; Karoly, E. D.; Hodgson, E.; Rose, R. L. In Vitro Sulfoxidation of Thioether Compounds by Human Cytochrome P450 and Flavin-Contaning Monooxygenase Isoforms with Particular Reference to the CYP2C Subfamily. Drug Metab. Dispos. 2004, 32, 333-339.
12. Afzelius, L.; Zamora, I.; Ridderström, M.; Andersson, T. B.; Karlén, A.; Masimirembwa, C. M. Competitive CYP2C9 Inhibitors: Enzyme Inhibition Studies, Protein Homology Modeling, and Three-Dimensional Quantitative Structure-Activity Relationship Analysis. Mol. Pharmacol. 2001, 59, 909-919.
13. De Groot, M. J.; Ekins, S. Pharmacophore Modeling of Cytochromes P450. Adv. Drug Delivery Rev. 2002, 54, 367-383.
14. De Groot, M. J. Designing Better Drugs: Predicting Cytochrome P450 Metabolism. Drug Discovery Today 2006, 11, 601-606.
15. Rao. S.; Aoyama, R.; Schrag, M.; Trager, W. F.; Rettie, A.; Jones, J. P. A Refined 3-Dimensional QSAR of Cytochrome P450 2C9: Computational Predictions of Drug Interactions. J. Med. Chem. 2000, 43, 2789-2796.
16. De Groot, M. J.; Alex, A. A.; Jones, B. C. Development of a Combined Protein and Pharmacophore Model for Cytochrome P450 2C9. J. Med. Chem. 2002, 45, 1983-1993.
17. Zamora, I.; Afzelius, L.; Cruciani, G. Predicting Drug Metabolism: A Site of Metabolism Prediction Tool Applied to the Cytochrome P450 2C9. J. Med. Chem. 2003, 46, 2313-2324.
18. Williams, P. A.; Cosme, J.; Ward, A.; Angove, H. C.; Vinkovic, D. M.; Jhoti, H. Crystal Structure of Human Cytochrome P450 2C9 with Bound Warfarin. Nature 2003, 424, 464-468.
19. Wester, M. R.; Yano, J. K.; Schoch, G. A.; Yang, C.; Griffin, K. J.; Stout, C. D.; Johnson, E. F. The Structure of Human Cytochrome P450 2C9 Complexed with Flurbiprofen at 2.0 Å Resolution. J. Biol. Chem. 2004, 279, 35630-35637.
20. Prasad, J. C.; Goldstone, J. V.; Camacho, C. J.; Vajda, S.; Stegeman, J. J. Ensemble Modeling of Substrate Binding to Cytochromes P450: Analysis of Catalytic Differences between CYP1A Orthologs. Biochemistry 2007, 46, 2640-2654.
21. Miners, J. O.; Smith, K. J.; Robson, R. A.; McManus, M. E.; Veronese, M. E.; Birkett, D. J. Tolbutamide Hydroxylation by Human Liver Microsomes: Kinetic Characterisation and Relationship to Other Cytochrome P-450 Dependent Xenobiotic Oxidations. Biochem. Pharmacol. 1988, 37, 1137-1144.
22. Yap, C. W.; Chen, Y. Z. Prediction of Cytochrome P450 3A4, 2D6, and 2C9 Inhibitors and Substrates by Using Support Vector Machines. J. Chem. Inf. Model. 2005, 45, 982-992.
23. Omega, version 2.1; Openeye Scientific Software: Santa Fe, NM, 2006.
24. Böstrom, J.; Greenwood, J. R.; Gottfries, J. Assessing the Performance of Omega with Respect to Retrieving Bioactive Conformations. J. Mol. Graphics Modell. 2003, 21, 449-462.
25. Kirchmair, J.; Wolber, G.; Laggner, C.; Langer, T. Comparative Performance Assessment of the Conformational Model Generators Omega and Catalyst: A Large-Scale Survey on the Retrieval of Protein-Bound Ligand Conformations. J. Chem. Inf. Model. 2006, 46, 1848-1861.
26. ROCS, version 2.2; Openeye Scientific Software: Santa Fe, NM, 2006.
27. FRED, version 2.1.2; Openeye Scientific Software: Santa Fe, NM, 2005.
28. Sykes, M. J.; Sorich, M. J.; Miners, J. O. Molecular Modelling Approaches for the Prediction of the Nonspecific Binding of Drugs to Hepatic Microsomes. J. Chem. Inf. Model. 2006, 46, 2661-2673.
29. Tracy, T. S.; Rosenbluth, B. W.; Wrighton, S. A.; Gonzalez, F. J.; Korzekwa, K. R. Role of the Cytochrome P450 2C9 and an Allelic Variant in the 4′-Hydroxylation of (R)- and (S)-Flurbiprofen. Biochem. Pharmacol. 1995, 49, 1269-1275.
30. VIDA, version 2.1.2; Openeye Scientific Software: Santa Fe, NM, 2006.
31. Taguchi, K.; Konishi, T.; Nishikawa, H.; Kitamura, S. Identification of Human Cytochrome P450 Isoforms Involved in the Metabolism of S-2-[4-(3-Methyl-2-Thienyl)Phenyl]Propionic Acid. Xenobiotica 1999, 29, 899-907.
32. Mancy, A.; Broto, P.; Dijols, S.; Dansette, P. M.; Mansuy, D. The Substrate Binding Site of Human Liver Cytochrome P450 2C9: An Approach Using Designed Tienilic Acid Derivatives and Molecular Modeling. Biochemistry 1995, 34, 10365-10375.
33. Lopez Garcia, M. P.; Dansette, P. M.; Valadon, P.; Amar, C.; Beaune, P. H.; Guengerich, F. P.; Mansuy, D. Human-Liver Cytochromes P-450 Expressed in Yeast as Tools for Reactive-Metabolite Formation Studies. Oxidative Activation of Tienilic Acid by Cytochromes P-450 2C9 and 2C10. Eur. J. Biochem. 1993, 213, 223-232.
34. Nakajima, M.; Inoue, T.; Shimada, N.; Tokudome, S.; Yamamoto, T.; Kuroiwa, Y. Cytochrome P450 2C9 Catalyzes Indomethacin O-Demethylation in Human Liver Microsomes. Drug Metab. Dispos. 1998, 26, 261-266.
35. Furuta, S.; Akagawa, N.; Kamada, E.; Hiyama, A.; Kawabata, Y.; Kowata, N.; Inaba, A.; Matthews, A.; Hall, M.; Kurimoto, T. Involvement of CYP2C9 and UGT2B7 in the Metabolism of Zaltoprofen, a Nonsteroidal Anti-Inflammatory Drug, and its Lack of Clinically Significant CYP Inhibition Potential. Br. J. Clin. Pharmacol. 2002, 54, 295-303.
36. 2 Inhibitor Seratrodast (ABT-001). Drug Metab. Dispos. 1997, 25, 110-115.
37. Gentile, D. M.; Verhoeven, C. H. J.; Shimada, T.; Back, D. J. The Role of CYP2C in the In Vitro Bioactivation of the Contraceptive Steroid Desogestrel. J. Pharmacol. Exp. Ther. 1998, 287, 975-982.
38. Wang, B.; Sanchez, R. I.; Franklin, R. B.; Evans, D. C.; Huskey, S-E. W. The Involvement of CYP3A4 and CYP2C9 in the Metabolism of 17α- Ethinylestradiol. Drug Metab. Dispos. 2004, 32, 1209-1212.
39. Yasar, Ü.; Tybring, G.; Hidestrand, M.; Oscarson, M.; Ingelman-Sundberg, M.; Dahl, M-L.; Eliasson, E. Role of CYP2C9 Polymorphism in Losartan Oxidation. Drug Metab. Dispos. 2001, 29, 1051-1056.
40. Tougou, K.; Gotou, H.; Ohno, Y.; Nakamura, A. Stereoselective Glucuronidation and Hydroxylation of Etodolac by UGT1A9 and CYP2C9 in Man. Xenobiotica 2004, 34, 449-461.
41. Schmider, J.; Greenblatt, D. J.; Von Moltke, L. L.; Karsov, D.; Vena, R.; Friedman, H. L.; Shader, R. I. Biotransformation of Mestranol to Ethinyl Estradiol In Vitro: The Role of Cytochrome P-450 2C9 and Metabolie Inhibitors. J. Clin. Pharmacol. 1997, 37, 193-200.
42. Tsuda-Tsukimoto, M.; Ogasawara, Y.; Kume, T. Role of Human Liver Cytochrome P450 2C9 in the Metabolism of a Novel a4b1/a4b7 Dual Antagonist. Drug Metab. Pharmacokinet. 2005, 20, 127-134.
43. Fischer, V.; Johanson, L.; Heitz, F.; Tullman, R.; Graham, E.; Baldeck, J. P.; Robinson, W. T. The 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor Fluvastatin: Effect on Human Cytochrome P-450 and Implications for Metabolic Drug Interactions. Drug Metab. Dispos. 1999, 27, 410-416.
44. Bort, R.; Ponsoda, X.; Carrasco, E.; Gomez-Lechon, M. J.; Castell, J. V. Metabolism of Aceclofenac in Humans. Drug Metab. Dispos. 1996, 24, 834-841.
45. Bland, T. M.; Haining, R. L.; Tracy, T. S.; Callery, P. S. CYP2C-Catalyzed δ-(9)-Tetrahydrocannabinol Metabolism: Kinetics, Pharmacogenetics and Interaction with Phenytoin. Biochem. Pharmacol. 2005, 70, 1096-1103.
46. Prueksaritanont, T.; Tang, C.; Qiu, Y.; Mu, L.; Subramanian, R.; Lin, J. H. Effects of Fibrates on Metabolism of Statins in Human Hepatocytes. Drug Metab. Dispos. 2002, 30, 1280-1287.
47. 359 Variants: Enzyme Kinetic Study with Seven Substrates. Pharmacogenetics 2000, 10, 95-104.
48. Guo, Y.; Zhang, Y.; Wang. Y.; Chen, X.; Si, D.; Zhong, D.; Fawcett, J. P.; Zhou, H. Role of CYP2C9 and its Variants (CYP2C9*3 and CYP2C9*13) in the Metabolism of Lornoxicam in Humans. Drug Metab. Dispos. 2005, 33, 749-753.
49. Gilissen, R. A. H. J.; Ferrari, L.; Barnaby, R. J.; Kajbaf, M. Human Hepatic Metabolism of a Novel 2-carboxyindole Glycine Antagonist for Stroke: In Vitro-In Vivo Correlations. Xenobiotica 2000, 30, 843-856.
50. Otake, Y.; Walle, T. Oxidation of the Flavonoids Galangin and Kaempferide by Human Liver Microsomes and CYP1A1, CYP1A2, and CYP2C9. Drug Metab. Dispos. 2002, 30, 103-105.
51. Rifkind, A. B.; Lee, C.; Chang, T. K. H.; Waxman, D. J. Arachidonic Acid Metabolism by Human Cytochrome P450s 2C8, 2C9, 2E1, and 1A2: Regioselective Oxygenation and Evidence for a Role for CYP2C Enzymes in Arachidonic Acid Epoxygenation in Human Liver Microsomes. Arch. Biochem. Biophys. 1995, 320, 380-389.
52. Shon, J.-H.; Yoon, Y.-R.; Kim, M.-J.; Kim, K.-A.; Lim, Y.-C.; Liu, K.-H.; Shin, D.-H.; Lee, C.-H.; Cha, I.-J.; Shin, J.-G. Chlorpropamide 2-Hydroxylation is Catalysed by CYP2C9 and CYP2C19 In Vitro: Chlorpropamide Disposition is Influenced by CYP2C9, but not by CYP2C19 Genetic Polymorphism. Br. J. Clin. Pharmacol. 2005, 59, 552-563.
53. Chesné, C.; Guyomard, C.; Guillouzo, A.; Schmids, J.; Ludwig, E.; Sauter, T. Metabolism of Meloxicam in Human Liver Involves Cytochromes P4502C9 and 3A4. Xenobiotica 1998, 28, 1-13.
54. 450 2C9 and 3A4 as the Major Catalysts of Phenprocoumon Hydroxylation In Vitro. Eur. J. Clin. Pharmacol. 2004, 60, 173-182.
55. Bort, R.; Macé, K.; Boobis, A.; Gómez-Lechón, M. J.; Pfeifer, A.; Castell, J. Hepatic metabolism of Diclofenac: Role of Human CYP in the Minor Oxidative Pathways. Biochem. Pharmacol. 1999, 58, 787-796.
56. Thijssen, H. H.; Flinois, J. P.; Beaune, P. H. Cytochrome P4502C9 is the Principal Catalyst of Racemic Acenocoumarol Hydroxylation Reactions in Human Liver Microsomes. Drug Metab. Dispos. 2000, 28, 1284-1290.
57. Machinist, J. M.; Mayer, M. D.; Shet, M. S.; Ferrero, J. L.; Rodrigues, A. D. Identification of the Human Liver Cytochrome P450 Enzymes Involved in the Metabolism of Zileuton (ABT-077) and its N-dehydroxylated Metabolite, Abbott-66193. Drug Metab. Dispos. 1995, 23, 1163-1174.
58. Weaver, R. J.; Dickins, M.; Burke, D. M. Cytochrome P450 2C9 is Responsible for Hydroxylation of the Naphthoquinone Antimalarial Drug 58C80 in Human Liver. Biochem. Pharmacol. 1993, 46, 1183-1197.
59. Kim, K.-A.; Kim, M.-J.; Park, J.-Y.; Shon, J.-H.; Yoon, Y.-R.; Lee, S.-S.; Liu, K.-H.; Chun, J.-H.; Hyun, M.-H.; Shin, J.-G. Stereoselective Metabolism of Lansoprazole by Human Liver Cytochrome P450 Enzymes. Drug Metab. Dispos. 2003, 31, 1227-1234.
60. Von Moltke, L. L.; Greenblatt, D. J.; Granda, B. W.; Duan, S. X.; Grassi, J. M.; Venkatakrishnan, K.; Harmatz, J. S.; Shader, R. I. Zolpidem Metabolism In Vitro: Responsible Cytochromes, Chemical Inhibitors, and In Vivo Correlations. Br. J. Clin. Pharmacol. 1999, 48, 89-97.
61. Draper, A. J.; Hammock, B. D. Identification of CYP2C9 as a Human Liver Microsomal Linoleic Acid Epoxygenase. Arch. Biochem. Biophys. 2000, 376, 199-205.
62. Shou, M.; Krausz, K. W.; Gonzalez, F. J.; Gelboin, H. V. Metabolic Activation of the Potent Carcinogen Dibenzo[a,h]anthracene by cDNA-Expressed Human Cytochromes P450. Arch. Biochem. Biophys. 1996, 328, 201-207.
63. Tang, C.; Shou, M.; Mei, Q.; Rushmore, T. H.; Rodrigues, A. D. Major Role of Human Liver Microsomal Cytochrome P450 2C9 (CYP2C9) in the Oxidative Metabolism of Celecoxib, a Novel Cyclooxygenase-II Inhibitor. J. Pharmacol. Exp. Ther. 2000, 293, 453-459.
64. Hyland, R.; Jones, B. C.; Smith, D. A. Identification of the Cytochrome P450 Enzymes Involved in the N-Oxidation of Voriconazole. Drug Metab. Dispos. 2003, 31, 540-547.
65. Yanagihara, Y.; Kariya, S.; Ohtani, M.; Uchino, K.; Aoyama, T.; Yamamura, Y.; Iga, T. Involvement of CYP2B6 in N-Demethylation of Ketamine in Human Liver Microsomes. Drug Metab. Dispos. 2001, 29, 887-890.
66. Hyland, R.; Roe, E. G. H.; Jones, B. C.; Smith, D. A. Identification of the Cytochrome P450 Enzymes Involved in the N-Demethylation of Sildenafil. Br. J. Clin. Pharmacol. 2001, 17, 239-248.
67. Vickers, A. E. M.; Sinclair, J. R.; Zollinger, M.; Heitz, F.; Glänzel, U.; Johanson, L.; Fischer, V. Multiple Cytochrome P-450s Involved in the Metabolism of Terbinafine Suggest a Limited Potential for Drug-Drug Interactions. Drug Metab. Dispos. 1999, 27, 1029-1038.
68. Chiba, M.; Xu, X.; Nishime, J. A.; Balani, S. K.; Lin, J. H. Hepatic Microsomal Metabolism of Montelukast, a Potent Leukotriene D4 Receptor Antagonist in Humans. Drug Metab. Dispos. 1997, 25, 1022-1031.
69. Sadeque, A. J. M.; Fisher, M. B.; Korzekwa, K. R.; Gonzalez, F. J.; Rettie, A. E. Human CYP2C9 and CYP2A6 Mediate Formation of the Hepatotoxin 4-Ene-Valproic Acid. J. Pharmacol. Exp. Ther. 1997, 283, 698-703.
70. Marques-Soares, C.; Dijols, S.; Macherey, A.-C.; Wester, M. R.; Johnson, E. F.; Dansette, P. M.; Mansuy, D. Sulfaphenazole Derivatives as Tools for Comparing Cytochrome P450 2C5 and Human Cytochromes P450 2Cs: Identification of a New High Affinity Substrate Common to Those Enzymes. Biochemistry 2003, 42, 6363-6369.
71. Margolis, J. M.; O'Donnell, J. P.; Mankowski, D. C.; Ekins, S.; Obach, R. S. (R)-, (S)-, and Racemic Fluoxetine N-Demethylation by Human Cytochrome P450 Enzymes. Drug Metab. Dispos. 2000, 28, 1187-1191.
72. Brian, W. R.; Srivastava, P. K.; Umbenhauer, D. R.; Lloyd, R. S.; Guengerich, F. P. Expression of a Human Liver Cytochrome P-450 Protein with Tolbutamide Hydroxylase Activity in Saccharomyces cerevisiae. Biochemistry 1989, 28, 4993-4999.
73. Winter, H. R.; Wang, Y.; Unadkat, J. D. CYP2C8/9 Mediate Dapsone N-Hydroxylation at Clinical Concentrations of Dapsone. Drug Metab. Dispos. 2000, 28, 865-868.
74. Linnet, K.; Olesen, O. V. Metabolism of Clozapine by cDNA-Expressed Human Cytochrome P450 Enzymes. Drug Metab. Dispos. 1997, 25, 1379-1382.
75. Oldham, H. G.; Clarke, S. E. In Vitro Identification of the Human Cytochrome P450 Enzymes Involved in the Metabolism of R-(+)- and S-(-)-Carvedilol. Drug Metab. Dispos. 1997, 25, 970-977.
76. Postlind, H.; Danielson, A.; Lindgren, A.; Andersson, S. H. G. Tolterodine, a New Muscarinic Receptor Antagonist, is Metabolized by Cytochromes P450 2D6 and 3A in Human Liver Microsomes. Drug Metab. Dispos. 1998, 26, 289-293.
77. Jeurissen, S. M. F.; Bogaards, J. J. P.; Boersma, M. G.; Ter Horst, J. P. F.; Awad, H. M.; Fiamegos, Y. C.; Van Beek, T. A.; Alink, G. M.; Sudhölter, E. J. R.; Cnubben, N. H. P.; Rietjens, I. M. C. M. Human Cytochrome P450 Enzymes of Importance for the Bioactivation of Methyleugenol to the Proximate Carcinogen 1′-Hydroxymethyleugenol. Chem. Res. Toxicol. 2006, 19, 111-116.
78. Hu, Y.; Kupfer, D. Metabolism of the Endocrine Disruptor Pesticide-Methoxychlor by Human P450s: Pathways Involving a Novel Catechol Metabolite. Drug Metab. Dispos. 2002, 30, 1035-1042.
79. Ueng, Y.-F.; Hsieh, C.-H.; Don, M.-J.; Chi, C.-W.; Ho, L.-K. Identification of the Main Human Cytochrome P450 Enzymes Involved in Safrole 1′-Hydroxylation. Chem. Res. Toxicol. 2004, 17, 1151-1156.
80. Benetton, S. A.; Borges, V. M.; Chang, T. K. H.; McErlane, K. M. Role of Individual Human Cytochrome P450 Enzymes in the In Vitro Metabolism of Hydromorphone. Xenobiotica 2004, 34, 335-344.
81. Hargreaves, J. A.; Howald, W. N.; Racha, J. K.; Levy, R. H. Identification of Enzymes Responsible for the Metabolism of Phenobarbital. In Proceedings of the Seventh North American ISSX Meeting, San Diego, CA, 1996; International Society for the Study of Xenobiotics; p 259.
82. Becquemont, L.; Mouajjah, S.; Escaffre, O.; Beaune, P.; Funck-Brentano, C.; Jaillon, P. Cytochrome P-450 3A4 and 2C8 are Involved in Zopiclone Metabolism. Drug Metab. Dispos. 1999, 27, 1068-1073.
83. Ghahramani, P.; Ellis, S. W.; Lennard, M. S.; Ramsay, L. E.; Tucker, G. T. Cytochromes P450 Mediating the N-Demethylation of Amitriptyline. Br. J. Clin. Pharmacol. 1997, 43, 137-144.
84. Coller, J. K.; Krebsfaenger, N.; Klein, K.; Endrizzi, K.; Wolbold, R.; Lang, T.; Nussler, A.; Neuhaus, P.; Zanger, U. M.; Eichelbaum, M.; Murdter, T. E. The Influence of CYP2B6, CYP2C9 and CYP2D6 Genotypes on the Formation of the Potent Antioestrogen Z-4-Hydroxytamoxifen in Human Liver. Br. J. Clin. Pharmacol. 2002, 54, 157-167.
85. Grimm, S. W.; Stams, K. R.; Aaron, E. J. Zafirlukast is a Substrate for CYP2C9 and an Inhibitor of CYP2C9 and CYP3A In Vitro. Int. Soc. Study Xenobiot. Proc. 1996, 10, 392.
86. Miyazawa, M.; Shindo, M.; Shimada, T. Metabolism of (+)- and (-)-Limonenes to Respective Carveols and Perillyl Alcohols by CYP2C9 and CYP2C19 in Human Liver Microsomes. Drug Metab. Dispos. 2002, 30, 602-607.
87. McGaughey, G. B.; Sheridan, R. P.; Bayly, C. I.; Culberson, J. C.; Kreatsoulas, C.; Lindsley, S.; Maiorov, V.; Truchon, J.-F.; Cornell, W. D. Comparison of Topological, Shape, and Docking Methods in Virtual Screening. J. Chem. Inf. Model. 2007, 47, 1504-1519.